- Oops!Something went wrong.Please try again later.
New York, New York--(Newsfile Corp. - September 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ardelyx, Inc. (NASDAQ: ARDX) alleging that the Company violated federal securities laws.
Class Period: August 6, 2020 and July 19, 2021
Lead Plaintiff Deadline: September 28, 2021
No obligation or cost to you.
Learn more about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=19572&from=5.
Ardelyx, Inc. NEWS - ARDX NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Ardelyx, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Ardelyx you have until September 28, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Ardelyx securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96498.